These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 32086839)

  • 41. miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1.
    Li N; Nan CC; Zhong XY; Weng JQ; Fan HD; Sun HP; Tang S; Shi L; Huang SX
    Cell Physiol Biochem; 2018; 49(4):1329-1341. PubMed ID: 30205384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P4HA2 promotes proliferation, invasion, and metastasis through regulation of the PI3K/AKT signaling pathway in oral squamous cell carcinoma.
    Chi Z; Wang Q; Wang X; Li D; Tong L; Shi Y; Yang F; Guo Q; Zheng J; Chen Z
    Sci Rep; 2024 Jul; 14(1):15023. PubMed ID: 38951593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Huang Z; Su Q; Li W; Ren H; Huang H; Wang A
    J Genet Genomics; 2021 Jul; 48(7):582-594. PubMed ID: 34373220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of circular RNA hsa_circ_0063772 on proliferation, migration and invasion of oral squamous cell carcinoma cells].
    Wang F; Wang YF; Su W; Yang HJ; Yang HY
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2019 Aug; 54(8):561-567. PubMed ID: 31378036
    [No Abstract]   [Full Text] [Related]  

  • 45. WISP-1 promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-300 in human oral squamous cell carcinoma cells.
    Lin CC; Chen PC; Lein MY; Tsao CW; Huang CC; Wang SW; Tang CH; Tung KC
    Oncotarget; 2016 Mar; 7(9):9993-10005. PubMed ID: 26824419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abnormal downregulation of 10-formyltetrahydrofolate dehydrogenase promotes the progression of oral squamous cell carcinoma by activating PI3K/Akt/Rb pathway.
    Qu Y; He Y; Ruan H; Qin L; Han Z
    Cancer Med; 2023 Mar; 12(5):5781-5797. PubMed ID: 36336972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrin-α5 promoted the progression of oral squamous cell carcinoma and modulated PI3K/AKT signaling pathway.
    Fan QC; Tian H; Wang Y; Liu XB
    Arch Oral Biol; 2019 May; 101():85-91. PubMed ID: 30909080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NCAPD2 promotes the malignant progression of oral squamous cell carcinoma via the Wnt/β-catenin pathway.
    Ma P; Yu H; Zhu M; Liu L; Cheng L; Han Z; Jin W
    Cell Cycle; 2024 Mar; 23(5):588-601. PubMed ID: 38743408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LncRNA MEG3 suppresses migration and promotes apoptosis by sponging miR-548d-3p to modulate JAK-STAT pathway in oral squamous cell carcinoma.
    Tan J; Xiang L; Xu G
    IUBMB Life; 2019 Jul; 71(7):882-890. PubMed ID: 30809930
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.
    Uesugi A; Kozaki K; Tsuruta T; Furuta M; Morita K; Imoto I; Omura K; Inazawa J
    Cancer Res; 2011 Sep; 71(17):5765-78. PubMed ID: 21795477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclocommunol induces apoptosis in human oral squamous cell carcinoma partially through a Mcl-1-dependent mechanism.
    Weng JR; Bai LY; Ko HH; Tsai YT
    Phytomedicine; 2018 Jan; 39():25-32. PubMed ID: 29433680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.
    Zhu H; Diao S; Lim V; Hu L; Hu J
    Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):509-516. PubMed ID: 30939187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-dose TNF-α promotes angiogenesis of oral squamous cell carcinoma cells via TNFR2/Akt/mTOR axis.
    Li S; Liu W; Liu J; Yang Z; Zhang L; Nie F; Yang P; Guo H; Yang C
    Oral Dis; 2024 Jul; 30(5):3004-3017. PubMed ID: 37964399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy.
    Lee YR; Wu WC; Ji WT; Chen JY; Cheng YP; Chiang MK; Chen HR
    J Biomed Sci; 2012 Jan; 19(1):9. PubMed ID: 22283874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pitavastatin induces apoptosis in oral squamous cell carcinoma through activation of FOXO3a.
    Lee N; Tilija Pun N; Jang WJ; Bae JW; Jeong CH
    J Cell Mol Med; 2020 Jun; 24(12):7055-7066. PubMed ID: 32406610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy.
    Fang L; Wang H; Zhou L; Yu D
    Oral Oncol; 2011 Jan; 47(1):16-21. PubMed ID: 21109483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DKK2 promotes the progression of oral squamous cell carcinoma through the PI3K/AKT signaling pathway.
    Guo W; Qu Y; Yu Y; Li X; Liang Z; Wang Z; Hu T; Zhou S
    Aging (Albany NY); 2024 May; 16(10):9204-9215. PubMed ID: 38795388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TAF1L promotes development of oral squamous cell carcinoma via decreasing autophagy-dependent apoptosis.
    Wang D; Qi H; Zhang H; Zhou W; Li Y; Li A; Liu Q; Wang Y
    Int J Biol Sci; 2020; 16(7):1180-1193. PubMed ID: 32174793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis.
    Ji YM; Zhou XF; Zhang J; Zheng X; Li SB; Wei ZQ; Liu T; Cheng DL; Liu P; Song K; Tan T; Zhu H; Guo JL
    Oncotarget; 2016 Mar; 7(12):14188-98. PubMed ID: 26893358
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Curcumin nanoemulsions inhibit oral squamous cell carcinoma cell proliferation by PI3K/Akt/mTOR suppression and miR-199a upregulation: A preliminary study.
    Liu W; Wang J; Zhang C; Bao Z; Wu L
    Oral Dis; 2023 Nov; 29(8):3183-3192. PubMed ID: 35689522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.